REG - Renalytix PLC - Holding(s) in Company

RenalytixAnnouncement

16/10/2025 14:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251016:nRSP7148Da&default-theme=true

RNS Number : 7148D  Renalytix PLC  16 October 2025

 

Renalytix plc

("Renalytix" or the "Company")

 

Holding(s) in Company

 

LONDON and NEW YORK, 16 October 2025 - Renalytix plc (LSE: RENX) (OTCQB:
RNLXY), announces that it has received a TR-1 notification from Harwood
Capital LLP following the recent admission of ordinary shares and increase in
the Company's total issued share capital (RNS 8264C: $4m balance sheet
improvement with bond conversion). The resulting crossing of a threshold is
due to an increase in the Company's total issued share capital, rather than
any disposal or acquisition of shares. The TR-1 notification is reproduced
below.

 

1. Issuer Details

ISIN

GB00BYWL4Y04

Issuer Name

RENALYTIX PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An event changing the breakdown of voting rights

3. Details of person subject to the notification obligation

Name

Harwood Capital LLP

City of registered office (if applicable)

 

Country of registered office (if applicable)

 

 Name                                            City of registered office  Country of registered office
 Harwood Capital Management (Gibraltar) Limited  Gibraltar                  Gibraltar
 Harwood Capital LLP                             London                     United Kingdom

4. Details of the shareholder

 Name                                                   City of registered office  Country of registered office
 North Atlantic Smaller Companies Investment Trust Plc  London                     United Kingdom
 Oryx International Growth Fund Limited                 Guernsey                   Guernsey
 Harwood Capital LLP                                    London                     United Kingdom

5. Date on which the threshold was crossed or reached

15-Oct-2025

6. Date on which Issuer notified

15-Oct-2025

7. Total positions of person(s) subject to the notification obligation

                                                                            % of voting rights attached to shares (total of 8.A)  % of voting rights through financial instruments (total of 8.B 1 + 8.B 2)  Total of both in % (8.A + 8.B)  Total number of voting rights held in issuer
 Resulting situation on the date on which threshold was crossed or reached  3.903000                                              0.000000                                                                   3.903000                        17061345
 Position of previous notification (if applicable)                          4.411130                                              0.000000                                                                   4.411130

8. Notified details of the resulting situation on the date on which the
threshold was crossed or reached

8A. Voting rights attached to shares

 Class/Type of shares ISIN code(if possible)  Number of direct voting rights (DTR5.1)  Number of indirect voting rights (DTR5.2.1)  % of direct voting rights (DTR5.1)  % of indirect voting rights (DTR5.2.1)
 GB00BYWL4Y04                                 11500000                                                                              2.631000
 GB00BYWL4Y04                                 4800000                                                                               1.098000
 GB00BYWL4Y04                                 761345                                                                                0.174000
 Sub Total 8.A                                17061345                                                                              3.903000%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

 Type of financial instrument  Expiration date  Exercise/conversion period  Number of voting rights that may be acquired if the instrument is  % of voting rights
                                                                            exercised/converted

 Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to
(DTR5.3.1R.(1) (b))

 Type of financial instrument  Expiration date  Exercise/conversion period  Physical or cash settlement  Number of voting rights  % of voting rights

 Sub Total 8.B2

9. Information in relation to the person subject to the notification
obligation

2. Full chain of controlled undertakings through which the voting rights
and/or the financial instruments are effectively held starting with the
ultimate controlling natural person or legal entities (please add additional
rows as necessary)

 Ultimate controlling person        Name of controlled undertaking                         % of voting rights if it equals or is higher than the notifiable threshold  % of voting rights through financial instruments if it equals or is higher  Total of both if it equals or is higher than the notifiable threshold
                                                                                                                                                                       than the notifiable threshold
 Christopher Harwood Bernard Mills  North Atlantic Smaller Companies Investment Trust Plc  2.631000                                                                                                                                                2.631000%
 Christopher Harwood Bernard Mills  Oryx International Growth Fund Limited                 1.098000                                                                                                                                                1.098000%
 Christopher Harwood Bernard Mills  Harwood Capital LLP                                    0.174000                                                                                                                                                0.174000%

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

 

12. Date of Completion

15/10/2025

13. Place Of Completion

London Stock Exchange

 

For further information, please contact:

 

 Renalytix plc                                     www.renalytix.com (http://www.renalytix.com)
 James McCullough, CEO                             Via Walbrook PR

 SP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker)                   Tel: +44 (0)20 3470 0470
 Jeff Keating / David Hignell (Corporate Finance)

 Vadim Alexandre (Corporate Broking)

 Oberon Capital (Joint Broker)                     Tel: +44 (0)20 3179 5300
 Mike Seabrook / Nick Lovering

 Walbrook PR Limited                               Tel: 020 7933 8780 or renalytix@walbrookpr.com
                                                   (mailto:renalytix@walbrookpr.com)
 Paul McManus / Alice Woodings                     Mob: 07980 541 893 / 07407 804 654

 

About Renalytix (www.renalytix.com)

Renalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled in
vitro diagnostics company, focused on optimizing clinical management of kidney
disease to drive improved patient outcomes. Renalytix has received FDA
approval and Medicare reimbursement for kidneyintelX.dkd which is now offered
commercially in the United States.

 

Unrecognized and uncontrolled kidney disease remains one of the largest
barriers to controlling cost and suffering in the United States and the United
Kingdom's medical system, affecting over 14 million and 8 million people,
respectively. After five years of development and clinical validation,
kidneyintelX.dkd is the only FDA-approved and Medicare reimbursed prognostic
tool capable of understanding a patient's risk with kidney disease early where
treatment has maximal effect. kidneyintelX.dkd is now being deployed across
large physician group practices and health systems in select regions of the
United States.

 

The over 15,000 patients that have been tested by kidneyintelX.dkd have
produced a substantial body of real-world performance data. In patient
populations where kidneyintelX.dkd has been deployed, a demonstrated and
significant increase in diagnosis, prognosis, and treatment rates have been
recorded. kidneyintelX.dkd now has full reimbursement established by Medicare,
the largest insurance payer in the United States, at $950 per reportable
result. kidneyintelX.dkd is also recommended for use in the international
chronic kidney disease clinical guidelines (KDIGO).

 

KidneyIntelX is based on technology developed by Mount Sinai faculty and
licensed to Renalytix AI, Inc. Mount Sinai faculty members are co-founders and
equity owners in the Company. In addition, the Icahn School of Medicine at
Mount Sinai has equity ownership in Renalytix. For information about the
kidneyintelX.dkd test, visit kidneyintelx.com (http://kidneyintelx.com/) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  HOLFLFFVIDLRLIE



            Copyright 2019 Regulatory News Service, all rights reserved